NCT00876850View on ClinicalTrials.gov

Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

August 31, 2010

Conditions
Skin Structures and Soft Tissue Infections
Interventions
DRUG

PTK 0796

PTK 0796 100mg for injection; PTK 0796 tablet 150mg

DRUG

Linezolid

For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution

Sponsors
All Listed Sponsors
lead

Paratek Pharmaceuticals Inc

INDUSTRY